AR080703A1 - Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. - Google Patents
Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.Info
- Publication number
- AR080703A1 AR080703A1 ARP110100914A ARP110100914A AR080703A1 AR 080703 A1 AR080703 A1 AR 080703A1 AR P110100914 A ARP110100914 A AR P110100914A AR P110100914 A ARP110100914 A AR P110100914A AR 080703 A1 AR080703 A1 AR 080703A1
- Authority
- AR
- Argentina
- Prior art keywords
- tetrahidro
- heteroaril
- prostaglandine
- carbazol
- modulators
- Prior art date
Links
- 230000000172 allergic effect Effects 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical class 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Reivindicacion 1: un compuesto de formula (1) donde R1 representa a hidrogeno, alquilo C1-4, alcoxi C1-4, halogeno, trifluorometoxi o trifluorometilo; R2 representa a hidrogeno, alquilo C1-4, alcoxi C1-2-alquilo C2-3, fluoroalquilo C1-4 o cicloalquilo C3-6-alquilo C1-2; y R3 representa a un grupo heteroarilo insustituido o mono-, di- o tri-sustituido, donde los sustituyentes son elegidos independientemente del grupo constituido por halogeno, alquilo C1-4, cicloalquilo C3-6, alcoxi C1-4, fluoroalquilo C1-4 y fenilo; o una sal de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2010051228 | 2010-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080703A1 true AR080703A1 (es) | 2012-05-02 |
Family
ID=43929122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100914A AR080703A1 (es) | 2010-03-22 | 2011-03-21 | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8697869B2 (es) |
| EP (1) | EP2558447B1 (es) |
| JP (1) | JP5291265B2 (es) |
| KR (1) | KR101444572B1 (es) |
| CN (1) | CN102791689B (es) |
| AR (1) | AR080703A1 (es) |
| AU (1) | AU2011231208B2 (es) |
| BR (1) | BR112012024114B1 (es) |
| CA (1) | CA2790139C (es) |
| CL (1) | CL2012002570A1 (es) |
| CY (1) | CY1115800T1 (es) |
| DK (1) | DK2558447T3 (es) |
| ES (1) | ES2524079T3 (es) |
| HR (1) | HRP20141208T1 (es) |
| IL (1) | IL221977A (es) |
| MA (1) | MA34094B1 (es) |
| MX (1) | MX2012010820A (es) |
| MY (1) | MY183111A (es) |
| NZ (1) | NZ603108A (es) |
| PH (1) | PH12012501863A1 (es) |
| PL (1) | PL2558447T3 (es) |
| PT (1) | PT2558447E (es) |
| RU (1) | RU2562255C2 (es) |
| SG (1) | SG183835A1 (es) |
| SI (1) | SI2558447T1 (es) |
| TW (1) | TWI562987B (es) |
| WO (1) | WO2011117798A1 (es) |
| ZA (1) | ZA201207894B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY165623A (en) * | 2011-04-14 | 2018-04-18 | Idorsia Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| CN103450218B (zh) * | 2012-05-29 | 2015-12-23 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的吲哚类三并环衍生物 |
| ES2690782T3 (es) | 2012-10-24 | 2018-11-22 | Nyu Winthrop Hospital | Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro |
| EP2994119A1 (en) * | 2013-05-10 | 2016-03-16 | CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Compounds suitable for the treatment of myeloproliferative neoplasms |
| HRP20181555T1 (hr) * | 2014-03-17 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2 |
| RU2016140708A (ru) * | 2014-03-18 | 2018-04-18 | Идорсиа Фармасьютиклз Лтд | Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2 |
| PL3350179T3 (pl) * | 2015-09-15 | 2021-08-02 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
| CN111094988A (zh) | 2017-09-13 | 2020-05-01 | 普罗根尼蒂公司 | 先兆子痫生物标志物及相关系统和方法 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS |
| CN113995758B (zh) * | 2021-11-04 | 2023-06-02 | 中山大学 | 咔唑-嘧啶衍生物在制备治疗抗肿瘤药物中的应用 |
| WO2025038666A2 (en) * | 2023-08-13 | 2025-02-20 | GATC Health Corp | Compounds and methods for treating addiction |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808608A (en) | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| DE3631824A1 (de) | 1986-02-21 | 1988-03-31 | Bayer Ag | Cycloalkano(1.2-b)indol-sulfonamide |
| ID23053A (id) * | 1997-06-04 | 2000-01-20 | Lilly Co Eli | Karboksamida yang digunakan sebagai agonis 5-ht <if> |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| WO2001078697A2 (en) | 2000-04-12 | 2001-10-25 | Merck Frosst Canada & Co. | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| ES2272712T3 (es) | 2001-05-23 | 2007-05-01 | Merck Frosst Canada Ltd. | Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2. |
| BR0214958A (pt) | 2001-12-14 | 2004-12-28 | Zentaris Gmbh | Derivados de tetraidrocarbazol como ligandos para receptores acoplados à proteìna-g (gpcr) |
| DE10164564B4 (de) * | 2001-12-14 | 2007-05-16 | Zentaris Gmbh | Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR) |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| JPWO2003097042A1 (ja) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗剤 |
| JP4484108B2 (ja) | 2002-05-16 | 2010-06-16 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗作用を有する化合物 |
| GB2388540A (en) | 2002-05-17 | 2003-11-19 | Bayer Ag | New use of Ramatroban |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| MXPA05004715A (es) | 2002-10-30 | 2005-08-03 | Merck Frosst Canada Inc | Derivados de piridopirrolizina y piridoindolizina. |
| US20060089353A1 (en) | 2003-03-06 | 2006-04-27 | Maki Iwahashi | Indole derivative compounds and drugs containing the compounds as the active ingredient |
| WO2004103970A1 (en) | 2003-05-20 | 2004-12-02 | Merck Frosst Canada Ltd. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| WO2004111047A2 (en) | 2003-06-12 | 2004-12-23 | Merck Frosst Canada Ltd. | Cycloalkanepyrrolopyridines as dp receptor antagonists |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| WO2005033099A2 (en) | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| CA2542716A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds having crth2 antagonist activity |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| NZ548396A (en) | 2004-01-31 | 2010-06-25 | Actimis Pharmaceuticals Inc | Imidazo[1,2-C]pyrimidinylacetic acid derivatives |
| RU2387652C2 (ru) * | 2004-03-11 | 2010-04-27 | Актелион Фармасьютиклз Лтд | Производные тетрагидропиридоиндола |
| WO2005094816A1 (en) | 2004-03-11 | 2005-10-13 | Actelion Pharmaceuticals Ltd | Indol-1-yl-acetic acid derivatives |
| US20050234030A1 (en) | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| FR2869878B1 (fr) | 2004-05-04 | 2006-08-04 | Mecan Outil Sa Sa | Procede et dispositif d'emballage d'objets allonges fragiles |
| GB0412914D0 (en) | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| KR20070115865A (ko) | 2004-09-21 | 2007-12-06 | 아더시스 인코포레이티드 | Ｃｒｔｈ2 수용체 길항작용을 나타내는 벤즈이미다졸아세트산 및 이의 용도 |
| EP1805171A4 (en) | 2004-09-21 | 2009-05-13 | Wyeth Corp | CRTH2 RECEPTOR ANTAGONISM DISPLAYING INDIGENOUS ACIDS AND APPLICATIONS THEREOF |
| GB0427381D0 (en) | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
| PL1833791T3 (pl) | 2004-12-27 | 2011-12-30 | Actelion Pharmaceuticals Ltd | Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2 |
| DOP2006000016A (es) | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
| GB2422829A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| GB2422830A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| EP1852420B1 (en) | 2005-02-25 | 2012-10-17 | Ono Pharmaceutical Co., Ltd. | Indole compounds for treating respiratory disorders |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| EP1891075B1 (en) | 2005-05-24 | 2011-10-19 | Merck Serono SA | Tricyclic spiro derivatives as crth2 modulators |
| GB0512944D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
| WO2007010965A1 (ja) | 2005-07-22 | 2007-01-25 | Shionogi & Co., Ltd. | Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
| EP1916245B1 (en) | 2005-07-22 | 2011-10-26 | Shionogi & Co., Ltd. | Indole derivative having pgd2 receptor antagonist activity |
| US7696222B2 (en) | 2005-08-12 | 2010-04-13 | Merck Frosst Canada Ltd | Indole derivatives as CRTH2 receptor antagonists |
| US20070203209A1 (en) | 2005-08-18 | 2007-08-30 | Wilmin Bartolini | Useful indole compounds |
| JP5147401B2 (ja) | 2005-09-06 | 2013-02-20 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体 |
| GB0518783D0 (en) | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
| GB0521275D0 (en) | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
| GB0525141D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525143D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525144D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525337D0 (en) | 2005-12-13 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| US7741360B2 (en) | 2006-05-26 | 2010-06-22 | Astrazeneca Ab | Bi-aryl or aryl-heteroaryl substituted indoles |
| GB0611695D0 (en) | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
| PT2046740E (pt) | 2006-07-22 | 2012-08-28 | Oxagen Ltd | Compostos com atividade antagonista do crth2 |
| DK2066628T3 (da) | 2006-07-25 | 2011-02-07 | Sanofi Aventis | 2-Phenylindoler som antagonister af prostaglandin-D2-receptorer |
| KR101411820B1 (ko) | 2006-08-07 | 2014-06-24 | 액테리온 파마슈티칼 리미티드 | (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체 |
| MX2009006762A (es) | 2006-12-21 | 2009-08-20 | Argenta Discovery Ltd | Antagonistas crth2. |
| GB0625842D0 (en) | 2006-12-22 | 2007-02-07 | Argenta Discovery Ltd | Indolizine derivatives |
| CA2681409A1 (en) | 2007-03-21 | 2008-09-25 | Argenta Oral Therapeutics Limited | Indolizine acetic acid derivatives as crth2 antagonists |
| GB0719485D0 (en) | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
| GB0719521D0 (en) | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
| JP2011500584A (ja) | 2007-10-10 | 2011-01-06 | ケミエテック，エルエルシ− | Ｃｒｔｈ２受容体拮抗薬としての複素環化合物 |
| US20100280049A1 (en) | 2007-11-06 | 2010-11-04 | Amira Pharmaceuticals, Inc. | Antagonists of pgd2 receptors |
| GB0722216D0 (en) | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| GB0722203D0 (en) | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| PT2250161E (pt) | 2008-01-18 | 2014-01-21 | Atopix Therapeutics Ltd | Compostos tendo atividade antagonista de crth2 |
| EP2245010A1 (en) | 2008-01-18 | 2010-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles active on crth2 receptor |
| JP2011509991A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP2011088826A (ja) | 2008-01-31 | 2011-05-06 | Astellas Pharma Inc | 芳香族カルボン酸化合物 |
| US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
| EP2300425A4 (en) | 2008-06-24 | 2012-03-21 | Panmira Pharmaceuticals Llc | PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS |
| CA2728311A1 (en) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Aminotetrahydroindazoloacetic acids |
| CA2730390A1 (en) | 2008-07-15 | 2010-01-21 | F.Hoffmann-La Roche Ag | Aminotetrahydroindazoloacetic acids |
| US8637671B2 (en) | 2008-09-22 | 2014-01-28 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
| US8637541B2 (en) | 2008-09-22 | 2014-01-28 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
| US8546422B2 (en) | 2008-09-22 | 2013-10-01 | Merck Canada Inc. | Azaindole derivatives as CRTH2 receptor antagonists |
| WO2010039982A1 (en) | 2008-10-01 | 2010-04-08 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US20110311483A1 (en) | 2010-03-30 | 2011-12-22 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| MY165623A (en) | 2011-04-14 | 2018-04-18 | Idorsia Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
-
2011
- 2011-03-21 WO PCT/IB2011/051165 patent/WO2011117798A1/en not_active Ceased
- 2011-03-21 TW TW100109588A patent/TWI562987B/zh not_active IP Right Cessation
- 2011-03-21 KR KR1020127027402A patent/KR101444572B1/ko not_active Expired - Fee Related
- 2011-03-21 HR HRP20141208AT patent/HRP20141208T1/hr unknown
- 2011-03-21 SG SG2012064358A patent/SG183835A1/en unknown
- 2011-03-21 AR ARP110100914A patent/AR080703A1/es unknown
- 2011-03-21 MY MYPI2012004149A patent/MY183111A/en unknown
- 2011-03-21 JP JP2013500636A patent/JP5291265B2/ja not_active Expired - Fee Related
- 2011-03-21 MA MA35260A patent/MA34094B1/fr unknown
- 2011-03-21 EP EP11715042.5A patent/EP2558447B1/en not_active Not-in-force
- 2011-03-21 US US13/637,005 patent/US8697869B2/en not_active Expired - Fee Related
- 2011-03-21 DK DK11715042.5T patent/DK2558447T3/da active
- 2011-03-21 NZ NZ603108A patent/NZ603108A/en not_active IP Right Cessation
- 2011-03-21 MX MX2012010820A patent/MX2012010820A/es active IP Right Grant
- 2011-03-21 AU AU2011231208A patent/AU2011231208B2/en not_active Ceased
- 2011-03-21 CN CN201180013742.2A patent/CN102791689B/zh not_active Expired - Fee Related
- 2011-03-21 PL PL11715042T patent/PL2558447T3/pl unknown
- 2011-03-21 BR BR112012024114-1A patent/BR112012024114B1/pt not_active IP Right Cessation
- 2011-03-21 ES ES11715042.5T patent/ES2524079T3/es active Active
- 2011-03-21 CA CA2790139A patent/CA2790139C/en not_active Expired - Fee Related
- 2011-03-21 PT PT117150425T patent/PT2558447E/pt unknown
- 2011-03-21 RU RU2012144543/04A patent/RU2562255C2/ru not_active IP Right Cessation
- 2011-03-21 SI SI201130326T patent/SI2558447T1/sl unknown
- 2011-03-21 PH PH1/2012/501863A patent/PH12012501863A1/en unknown
-
2012
- 2012-09-19 IL IL221977A patent/IL221977A/en not_active IP Right Cessation
- 2012-09-20 CL CL2012002570A patent/CL2012002570A1/es unknown
- 2012-10-19 ZA ZA2012/07894A patent/ZA201207894B/en unknown
-
2014
- 2014-12-02 CY CY20141101005T patent/CY1115800T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080703A1 (es) | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. | |
| AR100137A1 (es) | Compuestos 4-amino-imidazoquinolina | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| PE20142461A1 (es) | Moduladores del receptor de estrogeno y sus usos | |
| AR092503A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR084173A1 (es) | Derivados oxazolil-metileter como agonistas del receptor alx | |
| AR067665A1 (es) | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR093921A1 (es) | Derivados de indol carboxamida como antagonistas del receptor p2x7 | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| AR091770A1 (es) | Indolcarbonitrilos moduladores selectivos de receptores androgenicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |